Hemorrhagic transformation of ischemic brain tissue after t-PA thrombolysis as detected by MRI may be asymptomatic, but impair neurological recovery

Journal of the Neurological Sciences

Volumn 272, Issue 1-2, 2008, Pages 136-142

  Kimura, Kazumi ^a   Iguchi, Yasuyuki ^a   Shibazaki, Kensaku ^a   Aoki, Junya ^a   Terasawa, Yuka ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Asymptomatic hemorrhage; MRI; Outcome; T2*; Tissue plasminogen activator

Indexed keywords

GLUCOSE; TISSUE PLASMINOGEN ACTIVATOR;

? RECANALIZATION; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CONVALESCENCE; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; HUMAN TISSUE; INFUSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEUROLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 48349142757     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.05.012     Document Type: Article

References (34)

1. Hacke W., Donnan G., Fieschi C., Kaste M., von Kummer R., Broderick J.P., et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
2. Tissue plasminogen activator for acute ischemic stroke. The national institute of neurological disorders and stroke rt-PA stroke study group. N Engl J Med 333 (1995) 1581-1587
3. Alexandrov A.V., Demchuk A.M., Felberg R.A., Christou I., Barber P.A., Burgin W.S., et al. High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored with 2-mHz transcranial Doppler monitoring. Stroke 31 (2000) 610-614
4. Delgado-Mederos R., Rovira A., Alvarez-Sabin J., Ribo M., Munuera J., Rubiera M., et al. Speed of tPA-induced clot lysis predicts DWI lesion evolution in acute stroke. Stroke 38 (2007) 955-960
5. Kim Y.S., Garami Z., Mikulik R., Molina C.A., and Alexandrov A.V. Early recanalization rates and clinical outcomes in patients with tandem internal carotid artery/middle cerebral artery occlusion and isolated middle cerebral artery occlusion. Stroke 36 (2005) 869-871
6. Molina C.A., Alexandrov A.V., Demchuk A.M., Saqqur M., Uchino K., and Alvarez-Sabin J. Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator. Stroke 35 (2004) 151-156
7. Rubiera M., Alvarez-Sabin J., Ribo M., Montaner J., Santamarina E., Arenillas J.F., et al. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke 36 (2005) 1452-1456
8. Zangerle A., Kiechl S., Spiegel M., Furtner M., Knoflach M., Werner P., et al. Recanalization after thrombolysis in stroke patients: predictors and prognostic implications. Neurology 68 (2007) 39-44
9. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA stroke study group. Stroke 28 (1997) 2109-2118
10. Clark W.M., Wissman S., Albers G.W., Jhamandas J.H., Madden K.P., and Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA 282 (1999) 2019-2026
11. Kent D.M., Hinchey J., Price L.L., Levine S.R., and Selker H.P. In acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous?. Stroke 35 (2004) 1141-1146
12. Dzialowski I., Pexman J.H., Barber P.A., Demchuk A.M., Buchan A.M., and Hill M.D. Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type in the Canadian alteplase for stroke effectiveness study registry. Stroke 38 (2007) 75-79
13. Kaur J., Zhao Z., Klein G.M., Lo E.H., and Buchan A.M. The neurotoxicity of tissue plasminogen activator?. J Cereb Blood Flow Metab 24 (2004) 945-963
14. Nagai N., De Mol M., Lijnen H.R., Carmeliet P., and Collen D. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation 99 (1999) 2440-2444
15. Wang X., Tsuji K., Lee S.R., Ning M., Furie K.L., Buchan A.M., et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 35 (2004) 2726-2730
16. Barber P.A., Hill M.D., Eliasziw M., Demchuk A.M., Pexman J.H., Hudon M.E., et al. Imaging of the brain in acute ischaemic stroke: comparison of computed tomography and magnetic resonance diffusion-weighted imaging. J Neurol Neurosurg Psychiatry 76 (2005) 1528-1533
17. Yamaguchi T., Mori E., Minematsu K., Nakagawara J., Hashi K., Saito I., et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan alteplase clinical trial (J-ACT). Stroke 37 (2006) 1810-1815
18. Larrue V., von Kummer R.R., Muller A., and Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian acute stroke study (ECASS II). Stroke 32 (2001) 438-441
19. Pialat J.B., Wiart M., Nighoghossian N., Adeleine P., Derex L., Hermier M., et al. Evolution of lesion volume in acute stroke treated by intravenous t-PA. J Magn Reson Imaging 22 (2005) 23-28
20. Demchuk A.M., Morgenstern L.B., Krieger D.W., Linda Chi T., Hu W., Wein T.H., et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 30 (1999) 34-39
21. Fiorelli M., Bastianello S., von Kummer R., del Zoppo G.J., Larrue V., Lesaffre E., et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke 30 (1999) 2280-2284
22. Motto C., Ciccone A., Aritzu E., Boccardi E., De Grandi C., Piana A., et al. Hemorrhage after an acute ischemic stroke. MAST-I collaborative group. Stroke 30 (1999) 761-764
23. Libman R., Kwiakowski T., Lyden P., Grotta J.C., Tilley B.C., Fagen S.C., et al. Asymptomatic hemorrhagic transformation of cerebral infarction does not worsen long-term outcome. J Stroke Cerebrovasc Dis 14 (2005) 50-54
24. Hacke W., Kaste M., Fieschi C., Toni D., Lesaffre E., von Kummer R., Boysen G., Bluhmki E., Hoxter G., Mahagne M.H., et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274 (1995) 1017-1025
25. Hacke W., Kaste M., Fieschi C., von Kummer R., Davalos A., Meier D., et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators. Lancet 352 (1998) 1245-1251
26. Hill M.D., and Buchan A.M. Thrombolysis for acute ischemic stroke: results of the Canadian alteplase for stroke effectiveness study. CMAJ 172 (2005) 1307-1312
27. Jaillard A., Cornu C., Durieux A., Moulin T., Boutitie F., Lees K.R., et al. Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E group. Stroke 30 (1999) 1326-1332
28. Wang X., Asahi M., and Lo E.H. Tissue type plasminogen activator amplifies hemoglobin-induced neurotoxicity in rat neuronal cultures. Neurosci Lett 274 (1999) 79-82
29. Gilligan A.K., Markus R., Read S., Srikanth V., Hirano T., Fitt G., et al. Baseline blood pressure but not early computed tomography changes predicts major hemorrhage after streptokinase in acute ischemic stroke. Stroke 33 (2002) 2236-2242
30. Ribo M., Montaner J., Molina C.A., Arenillas J.F., Santamarina E., Quintana M., et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 35 (2004) 2123-2127
31. Tanne D., Kasner S.E., Demchuk A.M., Koren-Morag N., Hanson S., Grond M., et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the multicenter rt-PA stroke survey. Circulation 105 (2002) 1679-1685
32. Dubey N., Bakshi R., Wasay M., and Dmochowski J. Early computed tomography hypodensity predicts hemorrhage after intravenous tissue plasminogen activator in acute ischemic stroke. J Neuroimaging 11 (2001) 184-188
33. Chan S., Kartha K., Yoon S.S., Desmond D.W., and Hilal S.K. Multifocal hypointense cerebral lesions on gradient-echo MR are associated with chronic hypertension. AJNR Am J Neuroradiol 17 (1996) 1821-1827
34. Kwa V.I., Franke C.L., Verbeeten Jr. B., and Stam J. Silent intracerebral microhemorrhages in patients with ischemic stroke. Amsterdam vascular medicine group. Ann Neurol 44 (1998) 372-377